Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 11:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 10,729 matching trials from the live ClinicalTrials.gov search.
Conditions
Multiple Myeloma
Interventions
Isatuximab, lenalidomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 72 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Terminated Phase 1Phase 2 Interventional Results available

Siplizumab for Sickle Cell Disease Transplant

NCT06078696
Conditions
Anemia, Sickle Cell
Interventions
Siplizumab, Exchange Transfusion, Total Body Irradiation, Stem Cell Infusion, Cyclophosphamide 50mg, Mesna, Sirolimus Oral Tablet, Rituximab or Biosimilar
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Active, not recruiting Not applicable Interventional

Quantra Point-of-Care Hemostasis Monitoring

NCT06328647
Conditions
Bleeding, Hemostatic Disorder
Interventions
POC Quantra QPlus System, Routine care
Device · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Multiple Myeloma
Interventions
HuLuc63
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
8
States / cities
Little Rock, Arkansas • Los Angeles, California • Chicago, Illinois + 5 more
Conditions
Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Decitabine and Cedazuridine, Venetoclax
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
60 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
67
States / cities
Coeur d'Alene, Idaho • Post Falls, Idaho • Sandpoint, Idaho + 55 more
Conditions
Sickle Cell Disease
Interventions
Plerixafor
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Leukemia
Interventions
filgrastim, cytarabine, etoposide, hydroxyurea, mitoxantrone hydrochloride, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
17 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2000
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Non-small Cell Lung Cancer
Interventions
Filgrastim-SD/01
Drug
Lead sponsor
Schwartzberg, Lee, M.D.
Individual
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
2
States / cities
Southaven, Mississippi • Memphis, Tennessee
Conditions
Myelodysplastic Syndromes
Interventions
CC-5013
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
38
States / cities
Scottsdale, Arizona • Tucson, Arizona • Berkeley, California + 28 more
Conditions
Sickle Cell Disease
Interventions
serial functional magnetic resonance imaging (MRI)
Diagnostic Test
Lead sponsor
University of Michigan
Other
Eligibility
5 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia
Interventions
Unmanipulated UCB, SR-1 UCB
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
2 Years to 35 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Myeloma
Interventions
DS-3032b
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hairy Cell Leukemia
Interventions
Moxetumomab Pasudotox (CAT 8015), CAT 8015 (Moxetumomab Pasudotox)
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
3
States / cities
Stanford, California • Chicago, Illinois • Bethesda, Maryland
Conditions
Neonatal Thrombocytopenia
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
0 Days to 6 Months
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Leukemia
Interventions
recombinant flt3 ligand
Biological
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
47
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 29 more
Conditions
Leukemia, Myeloid, Chronic
Interventions
Autologous HSP-70 Protein-Peptide Complex (AG-858) Plus Gleevec™.
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
11
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 8 more
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
66 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Cancer, Chronic Lymphocytic Leukemia, Diffuse Large Cell Lymphoma, Hematologic Malignancies, Hematology, Leukemia, Low Grade Lymphoma, Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma, Oncology, Oncology Patients, T Cell Lymphoma, Tumors
Interventions
AMG 319
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Hackensack, New Jersey • Durham, North Carolina • Salt Lake City, Utah
Conditions
Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease
Interventions
APL-2
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
8
States / cities
Whittier, California • Miami Lakes, Florida • Orange City, Florida + 5 more
Conditions
Coagulopathy
Interventions
Thromboelastography (TEG 6S)
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
3 Months to 18 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Relapsed Acute Myeloid Leukemia
Interventions
Imetelstat, Azacitidine, Venetoclax
Drug
Lead sponsor
Douglas Tremblay
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
New York, New York
Conditions
Anemia
Interventions
methoxy polyethylene glycol-epoetin beta [Mircera]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Maywood, Illinois + 10 more
Conditions
Sickle Cell Anemia, Beta Thalassemia
Interventions
TBI, Hydroxyurea, briquilimab, Filgrastim (G-CSF), Sirolimus, Alemtuzumab, Plerixafor
Radiation · Drug · Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
4 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Terminated Phase 1Phase 2 Interventional Results available

Stem Cell Transplantation for Fanconi Anemia

NCT00167206
Conditions
Fanconi Anemia
Interventions
Hematopoietic Stem Cell Transplant, Thymic Shielding During Radiation, Total Body Irradiation, Cyclophosphamide, Fludarabine
Procedure · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
1 Day to 18 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota